Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)

  • End date
    Nov 14, 2023
  • participants needed
  • sponsor
    Memorial Sloan Kettering Cancer Center
Updated on 14 June 2022


The investigator's want to find out if treatment with ibrutinib, rituximab, and lenalidomide are safe and better than the usual approach in patients with recurrent or refractory central nervous system lymphoma.

Condition Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)
Treatment Rituximab, Ibrutinib, Lenalidomide
Clinical Study IdentifierNCT03703167
SponsorMemorial Sloan Kettering Cancer Center
Last Modified on14 June 2022


Yes No Not Sure

Inclusion Criteria

Participants must be able to understand and be willing to sign a written informed consent document
Men and woman who are at least 18 years of age on the day of consenting to the study
Histologically documented PCNSL or histologically documented systemic diffuse large B-cell lymphoma (DLBCL)
Patients must have relapsed/refractory PCNSL or relapsed/refractory SCNSL
All patients need to have received at least one prior CNS directed therapy. There is no restriction on the number of recurrences
Patients with parenchymal lesions must have unequivocal evidence of disease progression on imaging (MRI of the brain or head CT) 21 days prior to study registration. For patients with leptomeningeal disease only, CSF cytology must document lymphoma cells and/or imaging findings consistent with CSF disease 21 days prior to study registration (at the discretion of the investigator)
Participants must have an ECOG performance status of 0, 1, or 2
Participants must have adequate bone marrow and organ function shown by
Absolute neutrophil count (ANC) ≥ 1.0 x 10^9/L
Platelets ≥ 75 x 10^9/L and no platelet transfusion within the past 21 days prior to study registration
Hemoglobin (Hgb) ≥ 8 g/dL and no red blood cell (RBC) transfusion within the past 21 days prior to study registration
International Normalized Ratio (INR) ≤ 1.5 and PTT (aPTT) ≤ 1.5 times the upper limit of normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal
Serum bilirubin ≤ 1.5 times the upper limit of normal; or total bilirubin ≤ 3 times the upper limit of normal with direct bilirubin within the normal range in patients with well documented Gilbert Syndrome
Serum creatinine ≤ 2 times the upper limit of normal
Escalation: calculated creatinine clearance(CrCl) ≥ 60ml/min using the Cockcroft-Gault equation (Men: CrCl (min/ml) = (140-age) X (actual weight in kg) / 72 X serum creatinine (mg/dL); Women: CrCl (ml/min) = (140-age) X (actual weight in kg) X 0.85 / 72 X serum creatinine (mg/dL))
Extension: calculated creatinine clearance(CrCl) ≥30ml/min using the Cockcroft-Gault equation (Men: CrCl (min/ml) = (140-age) X (actual weight in kg) / 72 X serum creatinine (mg/dL); Women: CrCl (ml/min) = (140-age) X (actual weight in kg) X 0.85 / 72 X serum creatinine (mg/dL))
Woman of reproductive potential must agree to use highly effective methods of birth
Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry. See section on Pregnancy and Reproduction
control during the period of therapy and for 30 days after the last dose of
Patients must be able to tolerate MRI/CT scans
the study drug. Men who are sexually active must agree to use highly effective
Patients must be able to tolerate lumbar puncture and/or Ommaya taps
contraception during the period of therapy and for 3 months after the last
Participants must have recovered to grade 1 toxicity from prior therapy
Participants should be able to submit up to 20 unstained formalin-fixed, paraffinembedded (FFPE) slides from the initial tissue diagnosis prior to study registration for confirmation of diagnosis and correlative studies
All study participants must be registered into the mandatory Revlimid REMS® program, and be willing and able to comply with the requirements of the REMS® program
Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program
NOTE: Prior autologous stem cell transplant as well as prior radiation to the CNS does NOT
prevent patients from enrollment into the trial

Exclusion Criteria

Patients with SCNSL actively receiving treatment for extra-CNS disease are excluded
Patient is concurrently using other approved or investigational antineoplastic agents
Patient requires more than 8 mg of dexamethasone daily or the equivalent
Patient has an active concurrent malignancy requiring active therapy
Patient has received chemotherapy, monoclonal antibodies or targeted anticancer
Patient is allergic to components of the study drug
therapy ≤ 4 weeks or 5 half-lives, whichever is shorter, or 6 weeks for nitrosourea or
mitomycin-C prior to starting the study drug, or the patient has not recovered from
the side effects of such therapy
Patient has received external beam radiation therapy to the CNS within 21 days of the
first dose of the study drug
Patient has a known bleeding diathesis (e.g. von Willebrand"s disease) or hemophilia
Patient is known to have human immunodeficiency virus (HIV) infection
The patient has been treated with radio- or toxin-immunoconjugates within 70 days of
Patient is known to have an uncontrolled active systemic infection
the first dose of the study drug
Patient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K
antagonists. Patients must be off warfarin-derivative anticoagulants for at least
seven days prior to starting the study drug. Low molecular weight heparin is allowed
Patients with congenital bleeding diathesis are excluded
Patient is taking a drug known to be a moderate and strong inhibitor or inducers of
the P450 isoenzyme CYP3A. Participants must be off P450/CYP3A inhibitors and inducers
Known hypersensitivity to ibrutinib, thalidomide or lenalidomide
for at least two weeks prior to starting the study drug
Females who are pregnant
Patient is using systemic immunosuppressant therapy, including cyclosporine A
tacrolimus, sirolimus, and other such medications, or chronic administration of > 5
mg/day or prednisone or the equivalent. Participants must be off immunosuppressant
therapy for at least 28 days prior to the first dose of the study drug
Patient has significant abnormalities on screening electrocardiogram (EKG) and active
and significant cardiovascular disease such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, hypertension, valvular disease, pericarditis
or myocardial infarction within 6 months of screening
Patient is known to have a history of active or chronic infection with hepatitis C
virus (HCV) or hepatitis B virus (HBV) as determined by serologic tests
Patient underwent major systemic surgery ≤ 4 weeks prior to starting the trial
treatment or who has not recovered from the side effects of such surgery, or who plan
to have surgery within 2 weeks of the first dose of the study drug
Patient is unable to swallow capsules or has a disease or condition significantly
affecting gastrointestinal function, such as malabsorption syndrome, resection of the
stomach or small bowel, or complete bowel obstruction
Patient has poorly controlled diabetes mellitus with a glycosylated hemoglobin >8% or
poorly controlled steroid-induced diabetes mellitus with a glycosylated hemoglobin of
>8%. (for patients who received a short-term, high-dose dexamethasone treatment course
prior to enrollment (<7 days), the HbA1c value can be rounded to the nearest whole
Patient has a life-threatening illness, medical condition, or organ system dysfunction
that, in the opinion of the investigator, could compromise the subject"s safety or put
the study outcomes at undue risk
Women who are pregnant or nursing (lactating), where pregnancy is defined as a state
of a female after conception until the termination of gestation, confirmed by a
positive serum hCG laboratory test of > 5 mIU/mL (See section on Pregnancy and
Patient has undergone prior allogenic stem cell transplant (autologous stem cell
transplant is NOT an exclusion)
The patient is unwell or unable to participate in all required study evaluations and
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note